The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Safety Risk with Higher Dose Tofacitnib

Safety Risk with Higher Dose Tofacitnib

March 6, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

An ongoing safety trial of tofacitinib (Xeljanz, Xeljanz XR) in patients with rheumatoid arthritis (RA) has found an increased risk of pulmonary embolism and death with higher dosing.1 In late February, the U.S. Food and Drug Administration (FDA) issued an alert that these reactions occurred in patients taking 10 mg of tofacitinib twice daily.

You Might Also Like
  • Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
  • Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death
  • FDA Clears Pfizer’s Xeljanz for Inflammatory Bowel Disease
Also By This Author
  • Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis

The FDA has not approved this dosing regime for RA. Currently, 10 mg of tofacitinib taken twice daily is approved only for patients with ulcerative colitis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Background: When tofacitinib was first FDA approved for RA patients, the FDA required the manufacturer to conduct a clinical safety trial, evaluating the risk of heart-related events, cancer and opportunistic infections. This study examined two doses: 10 mg twice daily and 5 mg twice daily in combination with methotrexate and in comparison with a tumor necrosis factor-alpha inhibitor. To participate, patients had to be at least 50 years old and have at least one cardiovascular risk factor. In the trial’s most recent analysis, an external data safety monitoring committee found an increased occurrence of pulmonary embolism and death in these patients.

Healthcare professionals should follow the tofacitinib prescribing recommendations for the specific condition being treated. Patients should be monitored for signs and symptoms of pulmonary embolism. Advise patients to seek medical attention immediately if they experience symptoms or signs of pulmonary embolism. These include sudden shortness of breath or breathing difficulty, chest or back pain, hemoptysis, diaphoresis and/or clammy or bluish colored skin.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients should not stop or change their tofacitinib dose without first talking to their healthcare professional.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. U.S. Food and Drug Administration. Drug safety and availability: Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate. 2019 Feb 25.

Filed Under: Drug Updates, Safety Tagged With: cardiovascular, death, Drug Safety, Food and Drug Administration, pulmonary embolism, safety warning, Tofacitinib, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
  • Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death
  • FDA Clears Pfizer’s Xeljanz for Inflammatory Bowel Disease
  • FDA Declines to Expand Approval of Pfizer Arthritis Drug Xeljanz

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)